Cargando…

吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究

BACKGROUND AND OBJECTIVE: Platinum-based chemotherapy is considered the standard treatment of advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy and safety of gemcitabine plus oxaliplatin (GO) versus gemcitabine plus cisplatin (GP) regimens as the 1(st) li...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000267/
https://www.ncbi.nlm.nih.gov/pubmed/21762628
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.05
_version_ 1783331663396208640
collection PubMed
description BACKGROUND AND OBJECTIVE: Platinum-based chemotherapy is considered the standard treatment of advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy and safety of gemcitabine plus oxaliplatin (GO) versus gemcitabine plus cisplatin (GP) regimens as the 1(st) line chemotherapy for elderly patients with advanced NSCLC. METHODS: Sixty-six advanced NSCLC patients confrmed with pathology or cytology, who had not received treatment, were randomly divided into GO group (The patients received gemcitabine 1, 000 mg/m(2) on day 1 and day 8 and oxaliplatin 130 mg/m(2) on day 1 by intravenous infusion, with 21 days as one cycle) and GP group (The patients received gemcitabine 1, 000 mg/m(2) on day 1 and day 8 and cisplatin 25 mg/m(2) on day 1, day 2 and day 3) by intravenous infusion, with 21 days as one cycle). All patients who received 2 or more cycles could be evaluated. RESULTS: Tere were no statistical differences between GO and GP groups in the efciency of disease (36.4% vs 40.6%, P=0.801), the median progression-free survival (24 weeks vs 18 weeks, P=0.565), the median survival time (44 weeks vs 36 weeks, P=0.918), but anemia at grade Ⅲ and Ⅳ (0 vs 33.3%, P < 0.001) and nausea/vomiting at grade Ⅲ and Ⅳ (0 vs 27.3%, P=0.004) were signifcantly different. CONCLUSION: The clinical efciency of GO and GP regimens as the 1(st) line chemotherapy for advanced NSCLC in elderly patients was similar, but the toxicity of GO regimen has the tendency to be more tolerable and safer.
format Online
Article
Text
id pubmed-6000267
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60002672018-07-06 吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Platinum-based chemotherapy is considered the standard treatment of advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy and safety of gemcitabine plus oxaliplatin (GO) versus gemcitabine plus cisplatin (GP) regimens as the 1(st) line chemotherapy for elderly patients with advanced NSCLC. METHODS: Sixty-six advanced NSCLC patients confrmed with pathology or cytology, who had not received treatment, were randomly divided into GO group (The patients received gemcitabine 1, 000 mg/m(2) on day 1 and day 8 and oxaliplatin 130 mg/m(2) on day 1 by intravenous infusion, with 21 days as one cycle) and GP group (The patients received gemcitabine 1, 000 mg/m(2) on day 1 and day 8 and cisplatin 25 mg/m(2) on day 1, day 2 and day 3) by intravenous infusion, with 21 days as one cycle). All patients who received 2 or more cycles could be evaluated. RESULTS: Tere were no statistical differences between GO and GP groups in the efciency of disease (36.4% vs 40.6%, P=0.801), the median progression-free survival (24 weeks vs 18 weeks, P=0.565), the median survival time (44 weeks vs 36 weeks, P=0.918), but anemia at grade Ⅲ and Ⅳ (0 vs 33.3%, P < 0.001) and nausea/vomiting at grade Ⅲ and Ⅳ (0 vs 27.3%, P=0.004) were signifcantly different. CONCLUSION: The clinical efciency of GO and GP regimens as the 1(st) line chemotherapy for advanced NSCLC in elderly patients was similar, but the toxicity of GO regimen has the tendency to be more tolerable and safer. 中国肺癌杂志编辑部 2011-07-20 /pmc/articles/PMC6000267/ /pubmed/21762628 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.05 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
title 吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
title_full 吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
title_fullStr 吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
title_full_unstemmed 吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
title_short 吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
title_sort 吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000267/
https://www.ncbi.nlm.nih.gov/pubmed/21762628
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.05
work_keys_str_mv AT jíxītābīnliánhéàoshālìbóhuòshùnbóyīxiànzhìliáolǎoniánwǎnqīfēixiǎoxìbāofèiáidesuíjīyánjiū
AT jíxītābīnliánhéàoshālìbóhuòshùnbóyīxiànzhìliáolǎoniánwǎnqīfēixiǎoxìbāofèiáidesuíjīyánjiū
AT jíxītābīnliánhéàoshālìbóhuòshùnbóyīxiànzhìliáolǎoniánwǎnqīfēixiǎoxìbāofèiáidesuíjīyánjiū
AT jíxītābīnliánhéàoshālìbóhuòshùnbóyīxiànzhìliáolǎoniánwǎnqīfēixiǎoxìbāofèiáidesuíjīyánjiū